CCM
CNTA

CAAS Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

CAAS Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-62,500
Closed -$1.04M – 885
2021
Q3 		$1.04M Hold
62,500
– – 0.02% 472
2021
Q2 		$1.39M Buy
+62,500
New +$1.47M 0.02% 474

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

CAAS Capital Management's CNTA Position: Q4 2021 in Review

CAAS Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q4 2021, closing a stake of 62,500 shares — an estimated $1.04M sold.

CAAS Capital Management first reported a position in CNTA in Q2 2021 and held it in 2 quarters. The position peaked at $1.39M in Q2 2021. 47 funds tracked by Wall St. Rank hold CNTA as of Q4 2021.

  • CAAS Capital Management reported no remaining Centessa Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • CAAS Capital Management sold 62,500 Centessa Pharmaceuticals shares in Q4 2021, an estimated $1.04M.
  • CAAS Capital Management first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • CAAS Capital Management's Centessa Pharmaceuticals position peaked at $1.39M in Q2 2021.
  • 47 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.